Merck and Moderna’s personalized mRNA vaccine with Keytruda reduced melanoma recurrence in a 1,137-patient Phase 3 trial—the first late-stage win for an mRNA cancer vaccine.
FDA approves mFlusiva, Moderna’s first mRNA flu vaccine for adults 50+. Available soon for the 2026 season with strong trial results.
Moderna reported $145M Q2 revenue, beating $103M estimates on strong COVID vaccine sales. Shares fell after norovirus vaccine missed key trial goal.
Piper Sandler raised its price target on Moderna from $69 to $77, maintaining an Overweight rating. Strong momentum in the oncology pipeline is fueling the rally.
Decision due Aug 5, 2026. Potential 2026–27 launch.
Moderna names Ester Banque, ex-Zoetis/Novartis, as Chief Commercial Officer as it prepares for potential 2027 launches of combined flu-COVID, standalone flu, and norovirus vaccines. FDA advisory on mFLUSIVA this week.
